High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation.
Administration, Inhalation
Animals
BCG Vaccine
/ administration & dosage
Cytokines
/ metabolism
Disease Models, Animal
Disease Progression
Host-Pathogen Interactions
/ immunology
Immunity, Humoral
Immunization
Immunologic Memory
Macaca
Male
Mycobacterium tuberculosis
/ immunology
T-Lymphocyte Subsets
/ immunology
Tuberculosis
/ prevention & control
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 06 2021
10 06 2021
Historique:
received:
04
03
2021
accepted:
19
05
2021
entrez:
11
6
2021
pubmed:
12
6
2021
medline:
28
10
2021
Statut:
epublish
Résumé
This study describes the use of cynomolgus macaques of Chinese origin (CCM) to evaluate the efficacy and immunogenicity of the BCG vaccine against high dose aerosol Mycobacterium tuberculosis challenge. Progressive disease developed in three of the unvaccinated animals within 10 weeks of challenge, whereas all six vaccinated animals controlled disease for 26 weeks. Three unvaccinated animals limited disease progression, highlighting the intrinsic ability of this macaque species to control disease in comparison to macaques of other species and genotypes. Low levels of IFNγ were induced by BCG vaccination in CCM suggesting that IFNγ alone does not provide a sufficiently sensitive biomarker of vaccination in this model. An early response after challenge, together with the natural bias towards terminal effector memory T-cell populations and the contribution of monocytes appears to enhance the ability of CCM to naturally control infection. The high dose aerosol challenge model of CCM has value for examination of the host immune system to characterise control of infection which would influence future vaccine design. Although it may not be the preferred platform for the assessment of prophylactic vaccine candidates, the model could be well suited for testing post-exposure vaccination strategies and drug evaluation studies.
Identifiants
pubmed: 34112845
doi: 10.1038/s41598-021-90913-0
pii: 10.1038/s41598-021-90913-0
pmc: PMC8192909
doi:
Substances chimiques
BCG Vaccine
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12274Subventions
Organisme : Department of Health
Pays : United Kingdom
Références
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
Lancet. 2006 Apr 8;367(9517):1173-80
pubmed: 16616560
Tuberculosis (Edinb). 2008 Nov;88(6):631-40
pubmed: 18801705
Pharmaceutics. 2020 Apr 25;12(5):
pubmed: 32344890
Infect Immun. 2009 Oct;77(10):4631-42
pubmed: 19620341
J Clin Invest. 2012 Jan;122(1):303-14
pubmed: 22133873
JAMA. 1994 Mar 2;271(9):698-702
pubmed: 8309034
PLoS One. 2009 Jun 16;4(6):e5930
pubmed: 19529771
J Appl Microbiol. 2011 Aug;111(2):350-9
pubmed: 21651681
Front Immunol. 2017 Oct 05;8:1262
pubmed: 29051764
Tuberculosis (Edinb). 2016 Jan;96:1-12
pubmed: 26786648
Microbiol Spectr. 2016 Aug;4(4):
pubmed: 27726820
Front Immunol. 2017 Sep 19;8:1147
pubmed: 28974949
Vaccine. 2015 Aug 7;33(33):4130-40
pubmed: 26095509
PLoS One. 2017 Mar 8;12(3):e0171906
pubmed: 28273087
Nat Med. 2018 Feb;24(2):130-143
pubmed: 29334373
Vaccine. 2016 Oct 17;34(44):5298-5305
pubmed: 27622301
PLoS One. 2014 Feb 03;9(2):e87340
pubmed: 24498312
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1073-9
pubmed: 20558627
Nat Rev Immunol. 2008 Apr;8(4):247-58
pubmed: 18323851
J Med Primatol. 2012 Jun;41(3):191-201
pubmed: 22429048
Infect Immun. 2001 Apr;69(4):2666-74
pubmed: 11254633
Nat Med. 1996 Apr;2(4):430-6
pubmed: 8597953
Infect Immun. 2003 Oct;71(10):5831-44
pubmed: 14500505
Tuberculosis (Edinb). 2016 Dec;101:174-190
pubmed: 27865390
Nature. 2020 Jan;577(7788):95-102
pubmed: 31894150
Tuberculosis (Edinb). 2016 Jan;96:141-9
pubmed: 26723465
J Hyg (Lond). 1969 Sep;67(3):437-48
pubmed: 5258223
J Immunol. 2009 Jun 15;182(12):8047-55
pubmed: 19494330
N Engl J Med. 2019 Dec 19;381(25):2429-2439
pubmed: 31661198
Infect Immun. 2018 Jan 22;86(2):
pubmed: 28947646
J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):573-5
pubmed: 25247435
Front Immunol. 2020 Jan 10;10:2983
pubmed: 31998295
Tuberculosis (Edinb). 2008 Jan;88(1):31-8
pubmed: 18277396
Sci Rep. 2019 Mar 4;9(1):3340
pubmed: 30833652
Nat Med. 2007 Jul;13(7):843-50
pubmed: 17558415
J Infect. 2014 Dec;69(6):533-45
pubmed: 24975174
Infect Immun. 2018 Jan 22;86(2):
pubmed: 29203540
Cold Spring Harb Perspect Med. 2014 Sep 11;4(12):a018564
pubmed: 25213189
J Hyg (Lond). 1962 Jun;60:249-57
pubmed: 13904776
Clin Vaccine Immunol. 2010 Aug;17(8):1170-82
pubmed: 20534795
J Infect Dis. 2014 Feb 15;209(4):500-9
pubmed: 24041796
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11497-502
pubmed: 11562492
Front Immunol. 2019 Nov 01;10:2479
pubmed: 31736945
NPJ Vaccines. 2021 Jan 4;6(1):4
pubmed: 33397991
Clin Vaccine Immunol. 2013 May;20(5):663-72
pubmed: 23446219
PLoS Pathog. 2009 Apr;5(4):e1000392
pubmed: 19381260
NPJ Vaccines. 2021 Jan 4;6(1):3
pubmed: 33397986
Eur J Clin Microbiol Infect Dis. 2005 Aug;24(8):529-36
pubmed: 16133410
Tuberculosis (Edinb). 2009 Nov;89(6):405-16
pubmed: 19879805
Eur J Immunol. 2010 Aug;40(8):2211-20
pubmed: 20540114